The placebo effect in allergen-specific immunotherapy trials

Area of Science:

• Allergy and Immunology
• Clinical Trials
• Pharmacology

Background:

• Double-blind, placebo-controlled (DBPC) trials are the standard for evaluating treatment efficacy and tolerability.
• The placebo effect, a known factor in clinical studies, has not been systematically analyzed in allergen-specific immunotherapy (SIT).
• This study aimed to investigate the placebo response within SIT trials.

Purpose of the Study:

• To systematically examine the placebo effect in allergen-specific immunotherapy (SIT) studies.
• To quantify the placebo response using a symptom-medication score (SMS) over two years of treatment.
• To explore the influence of administration route and allergen exposure on the placebo effect.

Main Methods:

• Analysis of six DBPC SIT studies (five subcutaneous SIT (SCIT) and one sublingual SIT (SLIT)) involving 472 adult placebo-treated patients.
• Evaluation of the placebo effect based on changes in the SMS area under the curve after two years of placebo therapy.
• Assessment of pollen counts and allergen-specific IgG4 antibody levels.

Main Results:

• Placebo patients receiving subcutaneous immunotherapy (SCIT) showed a significant decrease in SMS, with the placebo effect reaching up to 41% in the second year.
• In contrast, the placebo effect in sublingual immunotherapy (SLIT) was minimal, around 1%.
• Allergen exposure inversely correlated with the placebo effect, and no changes in IgG4 levels were observed in placebo groups.

Conclusions:

• SIT studies exhibit a notable placebo effect, predominantly in SCIT, with considerable variation based on administration route and allergen exposure.
• The route of SIT administration (SCIT vs. SLIT) significantly influences the magnitude of the placebo effect.
• Findings highlight the differential impact of the placebo effect on SIT efficacy, modulated by administration method and environmental allergen exposure.